Related Experiment Video
Updated: May 5, 2026
09:57
Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
Published on: June 4, 2017
11.6K
Intracranial delivery of stem cells
Keith W Muir1, John Sinden, Erik Miljan
1Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK, keith.muir@glasgow.ac.uk.
Translational Stroke Research
|December 11, 2013
Summary
Choosing the right stem cell delivery method is crucial for clinical trials. Different routes impact patient risks and potential benefits, with direct intraparenchymal delivery safety under review.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Clinical Trial Design
Background:
- Stem cell therapy delivery methods significantly influence clinical trial outcomes.
- Current delivery route selection often relies on animal models for focal ischemia and central nervous system (CNS) transplantation.
- Limited comparative studies exist on the efficacy of various administration routes.
Purpose of the Study:
- To review the safety of direct intraparenchymal stem cell delivery in preliminary clinical trials.
- To highlight the importance of delivery method selection in cell therapy clinical trial design.
Main Methods:
- Review of safety data from preliminary clinical trials using direct intraparenchymal stem cell delivery.
- Analysis of factors influencing risk and benefit associated with different delivery methods.
Main Results:
- Direct intraparenchymal delivery has been utilized in initial clinical trials.
- The safety profile of this specific delivery method is being evaluated.
Conclusions:
- The method of stem cell delivery is a critical consideration for clinical trial design.
- Understanding the risks and benefits of different delivery routes, including intraparenchymal, is essential for advancing cell therapy.
